Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.15 AUD
−42.32 M AUD
0.00 AUD
225.59 M
About CLARITY PHARMACEUTICALS LTD
Sector
Industry
CEO
Michelle Parker
Website
Headquarters
Eveleigh
Founded
2010
ISIN
AU0000165375
FIGI
BBG011WVJ0L8
Clarity Pharmaceuticals Ltd. is a clinical stage radiopharmaceutical company. It engages in research and development and clinical stage evaluation of its portfolio of novel radiopharmaceuticals products. The company was founded by Matthew Harris on April 8, 2010 and is headquartered in Eveleigh, Australia.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of CU6 is 5.68 AUD — it has decreased by −4.86% in the past 24 hours. Watch CLARITY PHARMACEUTICALS LTD stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on ASX exchange CLARITY PHARMACEUTICALS LTD stocks are traded under the ticker CU6.
CU6 stock has fallen by −20.89% compared to the previous week, the month change is a −16.10% fall, over the last year CLARITY PHARMACEUTICALS LTD has showed a 331.64% increase.
We've gathered analysts' opinions on CLARITY PHARMACEUTICALS LTD future price: according to them, CU6 price has a max estimate of 10.00 AUD and a min estimate of 8.20 AUD. Watch CU6 chart and read a more detailed CLARITY PHARMACEUTICALS LTD stock forecast: see what analysts think of CLARITY PHARMACEUTICALS LTD and suggest that you do with its stocks.
CU6 stock is 8.20% volatile and has beta coefficient of 1.25. Track CLARITY PHARMACEUTICALS LTD stock price on the chart and check out the list of the most volatile stocks — is CLARITY PHARMACEUTICALS LTD there?
Today CLARITY PHARMACEUTICALS LTD has the market capitalization of 1.82 B, it has decreased by −16.39% over the last week.
Yes, you can track CLARITY PHARMACEUTICALS LTD financials in yearly and quarterly reports right on TradingView.
CLARITY PHARMACEUTICALS LTD is going to release the next earnings report on Feb 26, 2025. Keep track of upcoming events with our Earnings Calendar.
CU6 earnings for the last half-year are −0.06 AUD per share, whereas the estimation was −0.05 AUD, resulting in a −14.48% surprise. The estimated earnings for the next half-year are −0.07 AUD per share. See more details about CLARITY PHARMACEUTICALS LTD earnings.
CLARITY PHARMACEUTICALS LTD revenue for the last half-year amounts to 6.09 M AUD, despite the estimated figure of 4.93 M AUD. In the next half-year revenue is expected to reach 11.85 M AUD.
CU6 net income for the last half-year is −25.12 M AUD, while the previous report showed −17.20 M AUD of net income which accounts for −46.03% change. Track more CLARITY PHARMACEUTICALS LTD financial stats to get the full picture.
No, CU6 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, CU6 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CLARITY PHARMACEUTICALS LTD stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So CLARITY PHARMACEUTICALS LTD technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating CLARITY PHARMACEUTICALS LTD stock shows the buy signal. See more of CLARITY PHARMACEUTICALS LTD technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.